clinical trial · NCT07047612
ICP-332 in Subjects With Non-segmental Vitiligo
Beijing InnoCare Pharma Tech Co., Ltd.·phase3·recruiting·n = 603
Non Segmental VitiligoICP-332 TabletsICP-332 Placebo Tablets
brief summary
This a phase II/III randomized, double-blind, placebo-controlled, parallel group, adaptive design, multi-center study to evaluate the efficacy and safety of ICP-332 in subjects with non-segmental vitiligo。The study consisted an phase 2 part and an phase 3 part.
started
May 9, 2025
primary completion
Apr 1, 2029
completion
Apr 1, 2029
last updated
Aug 7, 2025
official title
A Phase II/III Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive Design, Multi-center Study to Evaluate the Efficacy and Safety of ICP-332 in Subjects With Non-segmental Vitiligo
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol